MaxCyte has completed the first dose cohort and initiated the second cohort in its first Phase I trial of MCY-M11, the first CARMA therapy in clinical development. No dose-limiting toxicities or safety concerns were observed in first patient cohort.
08 May 2019
Dosing advances to second cohort in CARMA Phase I
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Dosing advances to second cohort in CARMA Phase I
MaxCyte, Inc. (MXCT:LON) | 313 0 0.0% | Mkt Cap: 325.9m
- Published:
08 May 2019 -
Author:
Mick Cooper PhD -
Pages:
2
MaxCyte has completed the first dose cohort and initiated the second cohort in its first Phase I trial of MCY-M11, the first CARMA therapy in clinical development. No dose-limiting toxicities or safety concerns were observed in first patient cohort.